Metronidazole Baxter Healthcare (Metronidazole)

Metronidazole penetrates anaerobic cells and is reduced by bacterial enzymes to active metabolites. These metabolites bind to DNA, causing strand breakage and loss of helical structure, which blocks nucleic acid synthesis and leads to cell death. This mechanism selectively targets anaerobes and certain protozoa while sparing aerobic cells.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling when establishing the regimen.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no well‑controlled studies in pregnant women. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a prescriber should evaluate the risk‑benefit balance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details—including any cold‑chain requirements—and the necessary import documentation.

Metronidazole is a nitroimidazole that offers rapid bactericidal activity against most anaerobic bacteria and certain protozoa, often with a favorable safety profile compared with broader‑spectrum agents like clindamycin or carbapenems. Its oral and intravenous forms provide flexibility, but resistance patterns and infection site should guide selection alongside local antimicrobial stewardship recommendations.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Metronidazole Baxter Healthcare is supplied as a sterile injection for intravenous infusion. It is administered by a qualified healthcare professional, typically diluted in compatible IV fluids and infused over a period specified by the prescriber, based on the infection being treated and patient factors.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, and neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities, and therapy should be stopped if any severe adverse event occurs.

Metronidazole is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. It should also be avoided in individuals with severe hepatic impairment or those who are actively consuming alcohol due to the risk of a disulfiram‑like reaction.